/home/corante/public_html/pipeline/ en-us derek-lowe@sbcglobal.net 2009-11-20T07:54:14-05:00 hourly 1 2000-01-01T12:00+00:00 http://pipeline.corante.com/archives/2009/11/20/merck_shopping_in_the_uk.php So, according to this report, Merck is scouting out locations for a UK facility. No word if it's supposed to have a research component, but. . .as a correspondent points out, if only there were a large research campus that... 74153@/home/corante/public_html/pipeline/ Business and Markets 2009-11-20T07:54:14-05:00 http://pipeline.corante.com/archives/2009/11/11/go_spread_it_on_the_rosebushes.php Or perhaps one should wait until spring - it's the wrong season for high-nitrogen mixtures to be applied: Speaking at the Reuters Health Summit on Wednesday, Kindler said Pfizer has melded and reshaped its research and development facilities within 20... 74138@/home/corante/public_html/pipeline/ Business and Markets 2009-11-11T15:19:47-05:00 http://pipeline.corante.com/archives/2009/11/11/against_panic.php With the waves of layoffs going on, and all the nasty structural changes we're seeing in this business, it's easy to start feeling a toxic combination of fear and despair. And while I understand that, I'm going to try to... 74137@/home/corante/public_html/pipeline/ Business and Markets 2009-11-11T12:24:43-05:00 http://pipeline.corante.com/archives/2009/11/11/telling_the_layoff_story.php In an attempt to get the story out to a wider audience, I have a piece up at The Atlantic's Business site on the Pfizer layoffs, the J&J layoffs, and what's happening to the traditional expectations for the way research... 74136@/home/corante/public_html/pipeline/ Business and Markets 2009-11-11T11:22:32-05:00 http://pipeline.corante.com/archives/2009/11/11/pfizers_chemistry_head_count_really.php A reader who's (unfortunately) in a position to know the details sends along some numbers on Pfizer's chemistry shakeout. According to his figures, Pfizer (pre-Wyeth merger) had about 900 chemists. The Wyeth deal brought in about 350, but no one... 74135@/home/corante/public_html/pipeline/ Business and Markets 2009-11-11T07:43:47-05:00 http://pipeline.corante.com/archives/2009/11/10/pfizers_site_closures_an_analysis.php Pharmaconduct.org has another look at Pfizer's announcement yesterday, and tries to address some of the many unanswered questions left open by the company's press release. One thing that struck me (and many others) is that the company talked about "moving... 74133@/home/corante/public_html/pipeline/ Business and Markets 2009-11-10T07:23:22-05:00 http://pipeline.corante.com/archives/2009/11/09/pfizers_new_layout.php The company has issued a press release detailed which sites are staying, and which are leaving: Pfizer will have five main research sites that will serve as central hubs for research activities in BioTherapeutics, PharmaTherapeutics and Vaccines. These sites are:... 74131@/home/corante/public_html/pipeline/ Business and Markets 2009-11-09T13:50:59-05:00 http://pipeline.corante.com/archives/2009/11/09/selling_it_and_selling_it_hard.php There's a long, detailed article up over at Bloomberg on the recent run of huge fines for off-label promotion of drugs. Pfizer, Lilly, Bristol-Meyers Squibb, and Schering-Plough all get mentioned in great detail. And there's a key point from the... 74128@/home/corante/public_html/pipeline/ Business and Markets 2009-11-09T09:46:25-05:00 http://pipeline.corante.com/archives/2009/11/06/thoughts_on_what_used_to_be_scheringplough.php So what are we up to now, Day Three of Greater Merck? The merger with Schering-Plough went through earlier this week, and you won't get any more numbers by searching the stock tickers for SGP. I find that weird, since... 74127@/home/corante/public_html/pipeline/ Business and Markets 2009-11-06T08:55:48-05:00 http://pipeline.corante.com/archives/2009/11/03/jj_raises_the_ax.php Johnson & Johnson says that it could be cutting up to 8,000 jobs. This has been in the wind for a while, but I haven't had any reports yet of what it's doing on the ground to the research sites.... 74122@/home/corante/public_html/pipeline/ Business and Markets 2009-11-03T10:56:48-05:00 http://pipeline.corante.com/archives/2009/11/02/in_which_you_get_to_hear_the_phrase_hatchwaxman_again.php There's a constant running battle in the drug industry between the two kinds of pharmaceutical companies: the ones who discover the drugs first, and the ones who sell the drugs cheaply after the patents have expired. It surprises me still... 74120@/home/corante/public_html/pipeline/ Business and Markets 2009-11-02T07:45:21-05:00 http://pipeline.corante.com/archives/2009/10/30/fifty_years_of_scientific_history_for_you.php Here's a most interesting graph from the latest issue of Nature Reviews Drug Discovery. It's from an article on trying to discern trends from broad-scale literature analysis, and it's worth a separate blog post of its own (coming shortly). But... 74118@/home/corante/public_html/pipeline/ Drug Industry History 2009-10-30T08:50:16-05:00 http://pipeline.corante.com/archives/2009/10/29/the_best_ones_arent_over_here_any_more.php Here's one to get your attention: there's been a lot of arguing (on this blog and others) about the continual talk of shortages of scientists and engineers. That's a little hard to take for the number of people who've been... 74117@/home/corante/public_html/pipeline/ Business and Markets 2009-10-29T12:13:59-05:00 http://pipeline.corante.com/archives/2009/10/28/you_mean_you_dont_have_to_buy_them.php Johnson & Johnson's CEO has given an interview to the Financial Times explaining his company's strategy with acquisitions. And right now, that strategy is. . .not to make acquisitions. They see partnerships as making a lot more sense: “The cost... 74114@/home/corante/public_html/pipeline/ Business and Markets 2009-10-28T06:30:47-05:00 http://pipeline.corante.com/archives/2009/10/22/red_flags_in_biotech.php Xconomy has a useful two-part interview with Christopher Henney, who helped to found Icos, Dendreon, and Immunex. The part I found most interesting, naturally, was the section entitled "Five Red Flags of Biotech". (Note to the Xconony folks - the... 74108@/home/corante/public_html/pipeline/ Business and Markets 2009-10-22T06:32:21-05:00